Go Pro
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel Free RNA Stock Alerts

Avidity Biosciences (RNA) Competitors

Avidity Biosciences logo
$13.01 -0.64 (-4.69%)
As of 07/6/2026 04:00 PM Eastern
Compare

RNA vs. LBRX, SLDB, JANX, TBPH, and EVMN

Should you buy Avidity Biosciences stock or one of its competitors? MarketBeat compares Avidity Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avidity Biosciences include LB Pharmaceuticals (LBRX), Solid Biosciences (SLDB), Janux Therapeutics (JANX), Theravance Biopharma (TBPH), and Evommune (EVMN). These companies are all part of the "pharmaceutical products" industry.

How does Avidity Biosciences compare to LB Pharmaceuticals?

Avidity Biosciences (NASDAQ:RNA) and LB Pharmaceuticals (NASDAQ:LBRX) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

Avidity Biosciences presently has a consensus price target of $66.81, indicating a potential upside of 413.55%. LB Pharmaceuticals has a consensus price target of $38.40, indicating a potential upside of 14.94%. Given Avidity Biosciences' higher probable upside, equities analysts clearly believe Avidity Biosciences is more favorable than LB Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avidity Biosciences
1 Sell rating(s)
12 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.32
LB Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75

In the previous week, LB Pharmaceuticals had 3 more articles in the media than Avidity Biosciences. MarketBeat recorded 4 mentions for LB Pharmaceuticals and 1 mentions for Avidity Biosciences. LB Pharmaceuticals' average media sentiment score of 0.74 beat Avidity Biosciences' score of 0.00 indicating that LB Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Avidity Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
LB Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

LB Pharmaceuticals has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. LB Pharmaceuticals' return on equity of 0.00% beat Avidity Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Avidity Biosciences-3,650.39% -44.92% -39.57%
LB Pharmaceuticals N/A N/A N/A

LB Pharmaceuticals has lower revenue, but higher earnings than Avidity Biosciences. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avidity Biosciences$36.68M6.07-$322.30M-$0.97N/A
LB PharmaceuticalsN/AN/A-$25.20M-$1.73N/A

Summary

LB Pharmaceuticals beats Avidity Biosciences on 7 of the 10 factors compared between the two stocks.

How does Avidity Biosciences compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Avidity Biosciences (NASDAQ:RNA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

Solid Biosciences has higher earnings, but lower revenue than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Solid BiosciencesN/AN/A-$174.32M-$1.95N/A
Avidity Biosciences$36.68M6.07-$322.30M-$0.97N/A

Solid Biosciences presently has a consensus price target of $17.00, suggesting a potential upside of 53.57%. Avidity Biosciences has a consensus price target of $66.81, suggesting a potential upside of 413.55%. Given Avidity Biosciences' higher probable upside, analysts plainly believe Avidity Biosciences is more favorable than Solid Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Solid Biosciences
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.92
Avidity Biosciences
1 Sell rating(s)
12 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.32

Solid Biosciences has a beta of 2.36, indicating that its stock price is 136% more volatile than the broader market. Comparatively, Avidity Biosciences has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

In the previous week, Solid Biosciences had 3 more articles in the media than Avidity Biosciences. MarketBeat recorded 4 mentions for Solid Biosciences and 1 mentions for Avidity Biosciences. Solid Biosciences' average media sentiment score of 0.72 beat Avidity Biosciences' score of 0.00 indicating that Solid Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Solid Biosciences
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Avidity Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Solid Biosciences has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Avidity Biosciences' return on equity of -44.92% beat Solid Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Solid BiosciencesN/A -73.42% -61.13%
Avidity Biosciences -3,650.39%-44.92%-39.57%

81.5% of Solid Biosciences shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by insiders. Comparatively, 3.8% of Avidity Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Solid Biosciences beats Avidity Biosciences on 8 of the 15 factors compared between the two stocks.

How does Avidity Biosciences compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Avidity Biosciences (NASDAQ:RNA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

In the previous week, Janux Therapeutics had 1 more articles in the media than Avidity Biosciences. MarketBeat recorded 2 mentions for Janux Therapeutics and 1 mentions for Avidity Biosciences. Janux Therapeutics' average media sentiment score of 0.46 beat Avidity Biosciences' score of 0.00 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Janux Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Avidity Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Janux Therapeutics has a beta of 2.52, suggesting that its share price is 152% more volatile than the broader market. Comparatively, Avidity Biosciences has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Janux Therapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Janux Therapeutics' return on equity of -12.93% beat Avidity Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Janux TherapeuticsN/A -12.93% -12.23%
Avidity Biosciences -3,650.39%-44.92%-39.57%

Janux Therapeutics presently has a consensus target price of $40.15, suggesting a potential upside of 160.57%. Avidity Biosciences has a consensus target price of $66.81, suggesting a potential upside of 413.55%. Given Avidity Biosciences' higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than Janux Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Janux Therapeutics
2 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.53
Avidity Biosciences
1 Sell rating(s)
12 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.32

Janux Therapeutics has higher earnings, but lower revenue than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Janux Therapeutics$13.73M68.43-$113.62M-$1.84N/A
Avidity Biosciences$36.68M6.07-$322.30M-$0.97N/A

75.4% of Janux Therapeutics shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by insiders. Comparatively, 3.8% of Avidity Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Janux Therapeutics beats Avidity Biosciences on 12 of the 17 factors compared between the two stocks.

How does Avidity Biosciences compare to Theravance Biopharma?

Theravance Biopharma (NASDAQ:TBPH) and Avidity Biosciences (NASDAQ:RNA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

99.1% of Theravance Biopharma shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by company insiders. Comparatively, 3.8% of Avidity Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Theravance Biopharma currently has a consensus price target of $21.40, suggesting a potential upside of 25.88%. Avidity Biosciences has a consensus price target of $66.81, suggesting a potential upside of 413.55%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than Theravance Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Theravance Biopharma
0 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.13
Avidity Biosciences
1 Sell rating(s)
12 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.32

In the previous week, Theravance Biopharma had 6 more articles in the media than Avidity Biosciences. MarketBeat recorded 7 mentions for Theravance Biopharma and 1 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.00 beat Theravance Biopharma's score of -0.06 indicating that Avidity Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Theravance Biopharma
1 Very Positive mention(s)
3 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Avidity Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Theravance Biopharma has a net margin of 104.34% compared to Avidity Biosciences' net margin of -3,650.39%. Theravance Biopharma's return on equity of 18.84% beat Avidity Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Theravance Biopharma104.34% 18.84% 10.94%
Avidity Biosciences -3,650.39%-44.92%-39.57%

Theravance Biopharma has higher revenue and earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Theravance Biopharma$107.46M8.16$105.89M$2.207.73
Avidity Biosciences$36.68M6.07-$322.30M-$0.97N/A

Theravance Biopharma has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market. Comparatively, Avidity Biosciences has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

Summary

Theravance Biopharma beats Avidity Biosciences on 11 of the 17 factors compared between the two stocks.

How does Avidity Biosciences compare to Evommune?

Avidity Biosciences (NASDAQ:RNA) and Evommune (NYSE:EVMN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

In the previous week, Evommune had 4 more articles in the media than Avidity Biosciences. MarketBeat recorded 5 mentions for Evommune and 1 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.00 beat Evommune's score of -0.41 indicating that Avidity Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Avidity Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Evommune
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Evommune has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Evommune's return on equity of 0.00% beat Avidity Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Avidity Biosciences-3,650.39% -44.92% -39.57%
Evommune N/A N/A N/A

Evommune has lower revenue, but higher earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avidity Biosciences$36.68M6.07-$322.30M-$0.97N/A
Evommune$13M34.11-$68.87M-$9.50N/A

Avidity Biosciences presently has a consensus target price of $66.81, suggesting a potential upside of 413.55%. Evommune has a consensus target price of $45.63, suggesting a potential upside of 270.63%. Given Avidity Biosciences' higher probable upside, equities research analysts plainly believe Avidity Biosciences is more favorable than Evommune.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avidity Biosciences
1 Sell rating(s)
12 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.32
Evommune
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.79

Summary

Evommune beats Avidity Biosciences on 9 of the 13 factors compared between the two stocks.

Get Avidity Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RNA vs. The Competition

Export
MetricAvidity BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$222.55M$3.74B$6.92B$12.59B
Dividend YieldN/A2.16%2.66%6.52%
P/E Ratio-2.6221.6327.3524.81
Price / Sales6.07179.77507.7389.92
Price / CashN/A64.1829.6549.23
Price / Book1.208.5811.066.50
Net Income-$322.30M$23.68M$3.57B$336.03M
7 Day Performance-3.27%4.17%2.56%2.68%
1 Month Performance10.25%16.07%7.39%5.50%
1 Year Performance-54.83%63.53%34.13%25.01%

Avidity Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RNA
Avidity Biosciences
1.9307 of 5 stars		$13.01
-4.7%		$66.81
+413.5%		-55.3%$222.55M$36.68MN/A190
LBRX
LB Pharmaceuticals
1.4747 of 5 stars		$32.64
+2.3%		$38.40
+17.6%		N/A$915.37MN/AN/A16
SLDB
Solid Biosciences
3.0417 of 5 stars		$9.47
+1.9%		$17.00
+79.5%		+122.5%$914.60MN/AN/A100
JANX
Janux Therapeutics
3.3983 of 5 stars		$15.32
+2.5%		$40.15
+162.1%		-37.2%$911.11M$10MN/A30
TBPH
Theravance Biopharma
3.6697 of 5 stars		$17.06
-3.2%		$21.40
+25.4%		+52.0%$908.88M$107.46M7.75110

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:RNA) was last updated on 7/7/2026 by MarketBeat.com Staff.
From Our Partners
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Oil is settling in yuan now - here's what that means for gold
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel